For example, lenalidomide which induces IRF4 levels decrease [45], and ibrutinib which targets B-cell receptor signaling (Wilson WH et al., 2012, ASH Annual Meeting Abstract) have shown promising results in extracerebral ABC-DLBCL. The gene discussed is IRF4; the disease is diffuse large B-cell lymphoma.